These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 27376592)

  • 21. Everolimus-eluting bioresorbable scaffold implantation for the treatment of bifurcation lesions - Implications from early clinical experience during daily practice.
    Wiebe J; Dörr O; Bauer T; Liebetrau C; Boeder N; Möllmann H; Hamm CW; Nef HM
    Cardiovasc Revasc Med; 2016; 17(5):313-7. PubMed ID: 27085220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical utility of optical coherence tomography (OCT) in the optimisation of Absorb bioresorbable vascular scaffold deployment during percutaneous coronary intervention.
    Allahwala UK; Cockburn JA; Shaw E; Figtree GA; Hansen PS; Bhindi R
    EuroIntervention; 2015 Feb; 10(10):1154-9. PubMed ID: 24647105
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conformability in everolimus-eluting bioresorbable scaffolds compared with metal platform coronary stents in long lesions.
    Fam JM; Ishibashi Y; Felix C; Zhang BC; Diletti R; van Mieghem N; Regar E; van Domburg R; Onuma Y; van Geuns RJ
    Int J Cardiovasc Imaging; 2017 Dec; 33(12):1863-1871. PubMed ID: 28685314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Technology limitations of BRS in bifurcations.
    Fox J; Hossainy S; Rapoza R; Serruys PW
    EuroIntervention; 2015; 11 Suppl V():V155-8. PubMed ID: 25983156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Percutaneous coronary intervention: balloons, stents and scaffolds.
    Colleran R; Kastrati A
    Clin Res Cardiol; 2018 Aug; 107(Suppl 2):55-63. PubMed ID: 30039189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early U.S. Experience Following FDA Approval of the ABBOTT Vascular Bioresorbable Vascular Scaffold: Optimal Deployment Technique Using High Resolution Coronary Artery Imaging.
    Rizik DG; Padaliya BB
    J Interv Cardiol; 2016 Oct; 29(5):546-548. PubMed ID: 27492571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioresorbable vascular scaffolds in left main coronary artery disease.
    Everaert B; Capranzano P; Tamburino C; Seth A; van Geuns RJ
    EuroIntervention; 2015; 11 Suppl V():V135-8. PubMed ID: 25983148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
    Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D
    JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bioresorbable vascular scaffolds: From patient selection to optimal scaffold implantation; tips and tricks to minimize device failure.
    Tanaka A; Jabbour RJ; Latib A; Colombo A
    Catheter Cardiovasc Interv; 2016 Nov; 88(S1):10-20. PubMed ID: 27797460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of postdilatation on performance of bioresorbable vascular scaffolds in patients with acute coronary syndrome compared with everolimus-eluting stents: A propensity score-matched analysis from a multicenter "real-world" registry.
    Imori Y; D'Ascenzo F; Gori T; Münzel T; Fabrizio U; Campo G; Cerrato E; Napp LC; Iannaccone M; Ghadri JR; Kazemian E; Binder RK; Jaguszewski M; Csordas A; Capasso P; Biscaglia S; Conrotto F; Varbella F; Garbo R; Gaita F; Erne P; Lüscher TF; Moretti C; Frangieh AH; Templin C
    Cardiol J; 2016; 23(4):374-83. PubMed ID: 27515481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcome After Long-segment Stenting With Everolimus-eluting Bioresorbable Scaffolds Focusing on the Concept of Overlapping Implantation.
    Wiebe J; Dörr O; Liebetrau C; Bauer T; Wilkens E; Ilstad H; Boeder N; Elsässer A; Möllmann H; Hamm CW; Nef HM
    Rev Esp Cardiol (Engl Ed); 2016 Dec; 69(12):1144-1151. PubMed ID: 28134094
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.
    Serruys PW; Chevalier B; Dudek D; Cequier A; Carrié D; Iniguez A; Dominici M; van der Schaaf RJ; Haude M; Wasungu L; Veldhof S; Peng L; Staehr P; Grundeken MJ; Ishibashi Y; Garcia-Garcia HM; Onuma Y
    Lancet; 2015 Jan; 385(9962):43-54. PubMed ID: 25230593
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imaging assessment of bioresorbable vascular scaffolds.
    Sotomi Y; Suwannasom P; Tenekecioglu E; Collet C; Nakatani S; Okamura T; Muramatsu T; Ishibashi Y; Tateishi H; Miyazaki Y; Asano T; Katagiri Y; von Zur Muehlen C; Tanabe K; Kozuma K; Ozaki Y; Serruys PW; Onuma Y
    Cardiovasc Interv Ther; 2018 Jan; 33(1):11-22. PubMed ID: 28766253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of the learning curve on procedural results and acute outcome after percutaneous coronary interventions with everolimus-eluting bioresorbable scaffolds in an all-comers population.
    Wiebe J; Liebetrau C; Dörr O; Wilkens E; Bauer T; Elsässer A; Achenbach S; Möllmann H; Hamm CW; Nef HM
    Cardiovasc Revasc Med; 2015 Dec; 16(8):455-60. PubMed ID: 26428450
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design Principles of Bioresorbable Polymeric Scaffolds.
    Kossuth MB; Perkins LEL; Rapoza RJ
    Interv Cardiol Clin; 2016 Jul; 5(3):349-355. PubMed ID: 28582032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A review of bioresorbable scaffolds: hype or hope?
    Tan HC; Ananthakrishna R
    Singapore Med J; 2017 Sep; 58(9):512-515. PubMed ID: 27868135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complex bifurcation lesions: Randomized comparison of a fully bioresorbable modified t stenting strategy versus bifurcation reconstruction with a dedicated self-expanding stent in combination with bioresorbable scaffolds, an OCT study: Rationale and design of the COBRA II trial.
    Bennett J; Adriaenssens T; Desmet W; Dubois C
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):843-853. PubMed ID: 27184586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paving the way to a bioresorbable technology: Development of the absorb BRS program.
    Perkins LE; Kossuth MB; Fox JC; Rapoza RJ
    Catheter Cardiovasc Interv; 2016 Nov; 88(S1):1-9. PubMed ID: 27797462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bioresorbable vascular scaffold collapse causes subacute thrombosis.
    Ruiz-Salmerón RJ; Pereira S; de Araujo D
    J Invasive Cardiol; 2014 Jul; 26(7):E98-9. PubMed ID: 24993999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bioresorbable vascular scaffolds for the treatment of coronary artery disease: what have we learned from randomized-controlled clinical trials?
    Rizik DG; Hermiller JB; Simonton CA; Klassen KJ; Kereiakes DJ
    Coron Artery Dis; 2017 Jan; 28(1):77-89. PubMed ID: 27561169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.